BioCryst Pharmaceuticals, Inc.

BCRX Healthcare Drug Manufacturers Specialty & Generic

BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024. In the quarter to June 2026, revenue grew 33.6%, EPS grew 1,450.0%, free cash flow grew 153.2% and total debt rose 15.2%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

7.79 0.23 −2.87%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−3.5×
Dividend yield
—
F-score
7/9
Altman Z
1.83
Beneish M
−2.27
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
87.84% 91.07% (88.68%) 2.05%

+8 more TTM periods

Piotroski F-Score
5 4 7 5
ROA
(75.79%) (96.92%) 52.53% (1.87%)
ROIC
(610.55%) (356.26%) 245.61% 66.46%
Return on Tangible Assets
(135.02%) (244.12%) 121.56% (5.05%)
Average Days of Receivables
42.98 45.03 44.57 55.57
Free Cash Flow per Share
1.47 1.28 1.65 0.23
Free Cash Flow
373.93 310.92 345.45 47.86
Other line items

Show all line items

Columns are period end dates